Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 1,801–1,900 of 2,932
Dourado, C. P., Kamikawachi, R. C., Ferreira, M. J. P., Sartori, Â. L. B., Rodrigues, C. M., Spadari, C. D. C., Ishida, K., & Sannomiya, M. (2024) · Research Society and Development · doi:10.33448/rsd-v13i1.44604 · Cited by 3
Barroso, V. D. M., dos Reis, J. S., Stefani, H. A., & Ishida, K. (2024) · The Microbe · doi:10.1016/j.microb.2024.100062 · Cited by 3
Environmental and Social Determinants Related to Candidiasis
Morales-Ramírez, K. D. C., Ávila-Sosa, R., Cid-Pérez, T. S., Avelino-Flores, F., Duarte-Escalante, E., & Munguía-Pérez, R. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004600 · Cited by 7
Description of a Murine Model of Pneumocystis Pneumonia
Chesnay, A., Gonzalez, L., Parent, C., Désoubeaux, G., & Baranek, T. (2024) · Mycopathologia · doi:10.1007/s11046-024-00846-1 · Cited by 3
Musinguzi, B., Turyamuhika, L., Mwesigwa, A., Nalumaga, P. P., Kabajulizi, I., Njovu, I. K., Mwebesa, E., Luggya, T. S., Ocheng, F., Kateete, D. P., et al. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241255261 · Cited by 8
“4 , 32 39 The CD4 cell count is inversely proportional to oral Candida counts and this pre-disposes PLHIV with low CD4 to eventually develop OPC.”
BackgroundAdjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 mice
Brito, P. K. M. O., de Campos, G. Y., Guimarães, J. G., Machado, M. P., da Costa, L. S., Chica, J. E. L., Roque‐Barreira, M. C., & da Silva, T. A. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2360384 · Cited by 4
Kumar, D., Ansari, A., Rai, N., Gupta, A. K., & Kumar, N. (2024) · Plant Science Today · doi:10.14719/pst.3140 · Cited by 3
Velez-Haro, J. M., Pérez-Rodríguez, F., Velazquéz‐Marquez, S., Medina, H. R., & Velázquez-Márquez, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-62558-9_16 · Cited by 4
Mechanisms of action of Lactobacillus spp. in the treatment of oral candidiasis
Ferreira, R. L. P. S., Nova, B. G. V., do Carmo, M. S., & Abreu, A. G. (2024) · Brazilian Journal of Biology · doi:10.1590/1519-6984.282609 · Cited by 8
Molinero, R. L., Alava, K. H., Devoto, T. B., Sautua, F. J., Carmona, M., Cuestas, M. L., & Pena, G. A. (2024) · Medical Mycology · doi:10.1093/mmy/myae098 · Cited by 4
Reedy, J. M., Fernando, T., Awuor, S. O., Omwenga, E. O., Koutchma, T., & Mariita, R. M. (2024) · Hygiene · doi:10.3390/hygiene4030030 · Cited by 4
“The annual incidence of invasive candidiasis (from any form of Candida spp.) is estimated to be approximately 750,000 [57].”
InfluentialRevisiting threats associated with neglected and emerging fungal pathogens in sub-Saharan Africa
Akinola, S. A., Adeyemo, R. O., Bale, M. I., Eilu, E., Afodun, A. M., Akinola, R. A. A., Binuyo, M. O., Odoma, S., Suleiman, I. E., Adegboyega, T. T., et al. (2024) · Discover Public Health · doi:10.1186/s12982-024-00318-3 · Cited by 4
“Similar to Cryptococcus , Pneumocystis is a significant opportunistic infection in patients with impaired immunity [139].”
InfluentialMinimal domain peptides derived from enterocins exhibit potent antifungal activity
Cohen, D. G., Heidenreich, T. M., Schorey, J. W., Ross, J. N., Hammers, D. E., Vu, H. M., Moran, T. E., Winski, C. J., Stuckey, P. V., Ross, R. L., et al. (2024) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2024.1506315 · Cited by 3
“Infection rates have been rapidly increasing as social and medical factors such as those associated with COVID-19 cause escalated fungal infections (Bongomin et al., 2017; Basile et al., 2022; Hoenigl et al., 2022; Mina et al., 2022; Hlaing et al., 2023).”
InfluentialBeccacece, I., Burstein, V. L., Almeida, M. A., Gareca, J. C., Guasconi, L., Mena, C. J., Mary, V. S., Theumer, M. G., Cervi, L., Prinz, I., et al. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.11.011 · Cited by 3
Wei, Q., He, C., Peng, X., An, B.-K., Peng, M., Wang, X., Zhang, C., Lü, L., Sang, H., & Kong, Q. (2024) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-024-04234-1 · Cited by 3
Wagner, A. S., Smith, F. M., Bennin, D. A., Votava, J. A., Datta, R., Giese, M. A., Zhao, W., Skala, M. C., Fan, J., Keller, N. P., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012654 · Cited by 3
Functional analysis of Candida albicans Cdr1 through homologous and heterologous expression studies
Zhao, M., Lamping, E., Niimi, K., Niimi, M., & Cannon, R. D. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf012 · Cited by 3
“Fungal infections affect over 1 billion people globally and although many infections are superficial, invasive fungal infections (IFIs) kill more than 1.5 million people each year (Bongomin et al. 2017 ).”
InfluentialAzole resistance: patterns of amino acid substitutions in Candida sterol 14α-demethylase
Rao, R. S. P., Pinto, L., Shastry, R. P., Dakal, T. C., Suravajhala, P., Sashindran, V. K., & Ghate, S. D. (2025) · Antonie van Leeuwenhoek · doi:10.1007/s10482-025-02080-1 · Cited by 4
“Fungi cause considerable human morbidity and mortality, and are responsible for at least 13 million infections and 1.5 million deaths per year globally (Bongomin et al. 2017; Pfaller and Diekema 2007; Vallabhaneni et al. 2016).”
InfluentialClimate Change Impacts on Environmental Fungi: Human Health and Fungal Disease
Irizarry, P. R., Smith, D. F. Q., & Gusa, A. A. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_305 · Cited by 6
Priya, S. P., Chaitanya, N. C., Padmanabhan, V., Sridhar, S. B., Sivaswamy, V., Amalraj, S., Ayyanar, M., Murugesan, R., Kumar, R. P., & Prabhu, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100100 · Cited by 4
Ulloa, D., Núñez, C., Matamala, R., Martín, A. S., Ávila, D. P.-D., Mercado-Vides, J., Barandica, J. C. N., Aguirre, J., Effer, B. R., & Iturrieta‐González, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178732 · Cited by 3
“Although the incidence has decreased with the implementation of highly active antiretroviral therapy (HAART), it remains elevated among patients without access to treatment, mainly in developing countries [6], ranging from 2% to 60% in AIDS populations [7].”
Synthesis, in vitro antimicrobial activity, and in silico studies of 1-aminoalkyl-2-naphthols
Beyene, F., Mazumder, A., Tadesse, S., Asres, K., & Bisrat, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-23064-1 · Cited by 4
A Paradigm Shift in the Development of Anti-Candida Drugs
Gowda, D. V., Moin, A., Meenakshi, S. S., Manohar, M., Hemalatha, S., Siddaramaiah, H., Paranthaman, S., Rizvi, S. M. D., Hussain, T., & Kamal, M. A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191029145209 · Cited by 3
Epidemiology of Invasive Fungal Infections
Karakoç, Z. Ç. (2020) · Klimik Dergisi/Klimik Journal · doi:10.5152/kd.2019.53 · Cited by 3
“2/1000 hasta günü olarak saptanmış olup yakın zamandaki küresel tahminler yılda ~700 000 invazif kandidoz olgusu geliştiği yönündedir (8,9).”
Pathogenesis and Clinical Features of Fungal Keratitis (Review)
Belskaia, K. I., & Обрубов, А. С. (2021) · Ophthalmology in Russia · doi:10.18008/1816-5095-2021-1-12-19 · Cited by 3
Basak, T., Nath, V., Kumar, V., & Goyal, A. K. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500344 · Cited by 3
Antifungal activity of a novel 3-Alkylpyridine analog derived from Marine sponge alkaloids
Andrade, J. T., Lima, W. G., Barbosa, C. D. S., Gonçalves, A. M. M. N., SILVA, M. K. P., Morais, F. B., Palumbo, J. M. C., Viana, G. H. R., & Ferreira, J. M. S. (2021) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202120200944 · Cited by 3
Molecular analysis and essentiality of Aro1 shikimate biosynthesis multi-enzyme in Candida albicans
Stogios, P. J., Liston, S. D., Semper, C., Quade, B., Michalska, K., Evdokimova, E., Ram, S., Otwinowski, Z., Borek, D., Cowen, L. E., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101358 · Cited by 6
“C. albicans is a member of healthy human microbiota, but can also cause life-threatening systemic fungal infections, which occur predominantly in immunocompromised people (Low & Rotstein, 2011; Bongomin et al, 2017).”
Development and Characterization of Niosomal Gel for Topical Delivery of Luliconazole
Chatur, V. M., & Dhole, S. N. (2022) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/z9ryi9cxu5 · Cited by 3
“Fungal pathogens are one of the most common dermatological illnesses worldwide, with over 150 million people suffering from severe fungal infections that significantly affect their lives or are deadly, with a high frequency in developing and underdeveloped countries [1].”
BackgroundAntifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs
Blass, B. E., Puri, S., Sharma, R., & Day, B. M. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1000827 · Cited by 4
“The annual global incidence of invasive candidiasis is ~750,000 (Bongomin et al., 2017).”
BackgroundEffects of biofilm formation and plethora of Candida species causing ailments: a mini review
Aliyu, A. (2022) · Gadau Journal of Pure and Allied Sciences · doi:10.54117/gjpas.v1i2.27 · Cited by 4
Voropaev, A. D., Yekaterinchev, D. A., Urban, Y. N., Zverev, V. V., Nesvizhsky, Y. V., Александровна, В. Е., Likhanskaya, E. I., Afanasiev, M. S., & Afanasiev, S. S. (2022) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-ccm-1931 · Cited by 4
Rivas-Pinedo, P., Oñate, J., Berrío, I., Ramírez, A. M. C., Fernández-Suarez, H., Castañeda-Luquerna, X., Gualteros, S. M. R., Camacho‐Moreno, G., Saavedra-Trujillo, C. H., Enciso-Olivera, L. J., et al. (2022) · Infectio · doi:10.22354/24223794.1062 · Cited by 5
Stereotactic biopsy of a brain lesion caused by hormographiella aspergillata
Hounchonou, H. F., Runge, J., Ganser, A., et al. (2022) · Surgical Neurology International · doi:10.25259/sni_576_2022 · Cited by 3
“5 million deaths globally every year.[3] In contrast to superficial, cutaneous/mucosal, and subcutaneous fungal infections, IFIs affect organs such as heart, lung, brain, kidneys, or liver, especially in immunocompromised patients.”
BackgroundHovhannisyan, H., Rodríguez, A., Saus, E., Vaneechoutte, M., & Gabaldón, T. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1093178 · Cited by 3
Metabolomics in clinical diagnosis, prognosis, and treatment of infectious diseases
Azad, A. K., Hakim, A., Sohag, M. M. H., & Rahman, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99924-3.00003-0 · Cited by 4
Mycosis in the Philippines: Epidemiology, clinical presentation, diagnostics and interventions
Notarte, K. I., Pastrana, A. M., Ver, A. T., Velasco, J. V., Gellaco, M. M. L., & Pecundo, M. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99489-7.00005-6 · Cited by 4
Diniz-Lima, I., da Fonseca, L. M., dos Reis, J. S., Decotè-Ricardo, D., Morrot, A., Previato, J. O., Mendonça‐Previato, L., Freire-de-Lima, C. G., & Freire‐de‐Lima, L. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00936-0 · Cited by 4
Chen, N., He, Q. B., Ma, Y., Liu, S., Wei, H., & Peng, A. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1248 · Cited by 3
Naicker, S., Mohanlall, V., Ngubane, S., Mellem, J. J., & Mchunu, N. P. (2023) · Journal of Fungi · doi:10.3390/jof9060616 · Cited by 5
“In resource-limiting settings common in African countries, invasive fungal infections remain understudied and underdiagnosed despite their high mortality rates compared with other infectious diseases [4].”
BackgroundEvans, C., Ahmed, M., Beirne, D. F., McCann, M., Kavanagh, K. A., Devereux, M. M., Rooney, D. A., & Heaney, F. (2023) · BioMetals · doi:10.1007/s10534-023-00513-w · Cited by 3
“Immunocompromised individuals are a particular concern for opportunistic fungal infections and it is estimated that globally 150 million people are affected by serious fungal infections each year resulting in 1.6 million deaths (Bongomin et al. 2017).”
BackgroundInfluentialInvasive Fungal Infections in the Paediatric Intensive Care Unit: A Hong Kong Study
Li, M. W. T., Hon, K. E., Leung, K. K. Y., Hui, W. F., Lung, D. C., & Ha, S. (2023) · Current Pediatric Reviews · doi:10.2174/1573396320666230811092915 · Cited by 3
Galeane, M. C., Gomes, P. C., Singulani, J. D. L., et al. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0210 · Cited by 3
Wang, Y., Wan, X., Zhao, L., Jin, P., Zhang, J., Zhou, X., Ye, N., Wang, X., Pan, Y., & Xu, L. (2023) · Medical Mycology · doi:10.1093/mmy/myad097 · Cited by 3
Al-Dahlaki, N. O. M., & Al-Qaysi, S. A. S. (2023) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbagdad.2078 · Cited by 5
“Invasive fungal infections have become more common during the past two decades (1).”
BackgroundInfluentialGunawan, U., Ibrahim, S., Ivansyah, A. L., & Damayanti, S. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e111511 · Cited by 4
Filigheddu, M. T., Leonelli, M., Varando, G., Gómez-Bermejo, M. Á., Ventura‐Díaz, S., Gorospe, L., & Fortün, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.11.013 · Cited by 7
“…fungal infections by Aspergillus and other filamentous fungi (henceforth called AFF-IFI) have become a critical public health problem in recent decades [8], with an increase in filamentous fungal infections mainly due to Aspergillus spp, and to a lesser extent, Mucor spp and Fusarium spp [41].”
BackgroundKaur, H., Singh, K. J., Sharma, S., Das, M., Albert, V., Ojha, A. K., Singh, G., Hallur, V., Savio, J., Pamidimukkala, U., et al. (2024) · Journal of Fungi · doi:10.3390/jof10010042 · Cited by 5
Possible plant-based solutions for skin yeast infections
Lopes, A. I., Pintado, M. M., & Tavaria, F. K. (2024) · Fungal Biology Reviews · doi:10.1016/j.fbr.2023.100354 · Cited by 6
Investigation of selected functional properties of Grona trifloral biomass treated cotton fabric
Saniya, A., Divya, R., Sharmila, M., et al. (2024) · Biomass Conversion and Biorefinery · doi:10.1007/s13399-024-05426-3 · Cited by 3
“A worldwide assessment found that almost 150 million people had serious fungal and bacterial infections [2, 3].”
Palanivel, J., Mohapatra, M. M., Rajaram, M., Gochhait, D., Chakkalakkoombil, S. V., & Singh, R. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.2927 · Cited by 9
Design and Synthesis of Novel Amino and Acetamidoaurones with Antimicrobial Activities
Maio, A. D., Olleik, H., Courvoisier‐Dezord, E., Guillier, S., Neulat-Ripoll, F., Haudecoeur, R., Bolla, J., Casanova, M., Cavalier, J., Canaan, S., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13040300 · Cited by 4
“Overall, research on scaffold modifications has mainly focused on the substitution at the B-ring scaffold, e.g., with the introduction of either ferrocene [15], 5-nitroimidazole [16] or quinoline [17] groups, with a global tendency to retain naturally present hydroxy groups at the A-ring.”
BackgroundInfluentialCarbon Nanomaterials in Drug and Gene Delivery Potential: Focus on Fungal Infections
Kumar, P., Singh, R., Kaur, G., & Chawla, S. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0240-4_12 · Cited by 3
Singhal, E., Singh, R., Bhardwaj, P., & Kumari, M. (2024) · Journal of Medical and Scientific Research · doi:10.17727/jmsr.2024/12-2 · Cited by 4
ANTIFUNGAL RESISTANCE: A GROWING CONCERN
Firacative, C. (2023) · Acta Biológica Colombiana · doi:10.15446/abc.v28n3.104736 · Cited by 5
Khurana, S., & Arora, S. (2024) · Methods in microbiology · doi:10.1016/bs.mim.2024.05.011 · Cited by 3
Diving into freshwater microbial metabolites: Pioneering research and future prospects
Sachdeva, S., & Sarethy, I. P. (2024) · International Journal of Environmental Health Research · doi:10.1080/09603123.2024.2351153 · Cited by 6
“Although not often accentuated, around 1.5 million people die from fungi-related diseases each year, which are among the causes of morbidity from infectious illnesses (Bongomin et al. 2017).”
InfluentialAnkita, A., Thakur, S., Verma, R., Kumar, R., Khurana, N., Kaur, C., & Singh, G. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266319532240822050311 · Cited by 3
Advances in Dendritic-Cell-Based Vaccines against Respiratory Fungal Infections
Kulkarni, N. A., & Nanjappa, S. G. (2024) · Vaccines · doi:10.3390/vaccines12090981 · Cited by 6
“This mortality rate surpasses that of malaria and is nearly comparable to the deaths caused by HIV/AIDS and tuberculosis [2].”
ResultWinkler, M., Rhomberg, P. R., Fedler, K. A., Huband, M. D., Karr, M. H., Kimbrough, J. H., & Castanheira, M. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01207-24 · Cited by 4
Combatting antimicrobial resistance: Mechanisms, emerging therapies, and future directions
Abdelshafey, H. E., Abdalla, M. A., Eltayeb, E. E., Mohmmed, R. O., Younis, A., Musa, Y. A. M. A., Shekedrees, E. I., Madani, I. A., Eltayeb, O. A., & El‐Maradny, Y. A. (2024) · Microbial Biosystems · doi:10.21608/mb.2024.400342 · Cited by 3
“Globally, fungal infections affect over a billion individuals, causing a range of conditions from superficial and allergic infections to life-threatening diseases (Brown et al., 2012; Bongomin et al., 2017).”
Xi-hua, Y., Qin, X., Lulu, T., et al. (2025) · Mycoses · doi:10.1111/myc.70004 · Cited by 3
Chen, C., Wu, J.-H., Huang, H., Lu, P.-L., Tu, H., & Lin, S.-Y. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116805 · Cited by 4
Ramadan, L., & Harb, M. (2025) · Environmental Science Processes & Impacts · doi:10.1039/d5em00020c · Cited by 3
Pham, T. Q., Delorme, L., Cortaredona, S., Ranque, S., & Menu, E. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108206 · Cited by 4
Genetics and humoral responses of the immune system to Aspergillus fumigatus
Sanya, D. R. A., Jayachandran, K., & Onésime, D. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.06.007 · Cited by 3
Antifúngicos poliénicos. Mecanismo de acción y aplicaciones
Rivera-Toledo, E., Jiménez-Delgadillo, A. U., & Manzano–Gayosso, P. (2020) · Revista de la Facultad de Medicina UNAM · doi:10.22201/fm.24484865e.2020.63.2.02 · Cited by 3
Stimulation of surfactant exocytosis in primary alveolar type II cells by A. fumigatus
Schiefermeier-Mach, N., Perkhofer, S., Heinrich, L., & Haller, T. (2020) · Medical Mycology · doi:10.1093/mmy/myaa042 · Cited by 3
Alexandru Vasile, R. U. S. U., Penedo, B. Á., Schwarze, A.-K., & Trif, M. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92791 · Cited by 10
Go, H. C., Low, J. A., Khoo, K. S., & Sit, N. W. (2021) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-021-00981-z · Cited by 4
Kerion Celsi in a Nepalese Boy: An Underdiagnosed Cause of Scalp Swelling
Parajuli, R., Shrestha, A. L., Nayak, N., Gokhale, S., Gautam, K., & Subedi, S. (2021) · Case Reports in Infectious Diseases · doi:10.1155/2021/5527974 · Cited by 3
“)e burden of this disease has been estimated in 16 countries to date with a total of 21,073,423 cases, the majority of these being in subSaharan Africa and amongst school children.”
BackgroundSpecial Issue “Fungal Burden in Different Countries”
Richardson, M. D., & Cole, D. C. (2018) · Journal of Fungi · doi:10.3390/jof4030080 · Cited by 3
Chakrabarti, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_19 · Cited by 4
Li, Q., Kong, D., Wang, Y., Dou, Z., Huang, W., Hu, B., Dong, F., Jiang, H., Lv, Q., Zheng, Y., et al. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.104973 · Cited by 3
Li, Y., Li, S., Chen, M., Xiao, J., & Fang, H. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1074903 · Cited by 4
“However, recent years, the evolution of drug resistant strains, and emergence of new pathogens presents a new challenge (Bongomin et al., 2017; Perfect, 2017).”
Background(2021) · American Journal of Pure and Applied Biosciences · doi:10.34104/ajpab.021.01130118 · Cited by 3
Zamith‐Miranda, D., Amatuzzi, R. F., Martins, S. T., Vieira, A. Z., da Rocha, I. M., Rodrigues, M. L., Trentin, G., Almeida, F. B. D. R., Nakayasu, E. S., Nosanchuk, J. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.04.411843 · Cited by 3
“For the mRNA identification in the EVs, we combined the differential expression with reads coverage, so we performed the map reads to reference (C_auris_B8441_version_s01-m01-r10_genomic and C_auris_B8441_version_s01-m01-r10_other_features_plus_intergenic) using the following parameters: No masking, match score (1), m…”
MethodBabič, M. N., Brandão, J. C., & Gunde‐Cimerman, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21038-8 · Cited by 3
Ιωάννου, Μ., Hoving, D., Aramburu, I. V., de Vasconcelos, N. M., Temkin, M. I., Wang, Q., Vernardis, S. I., Demichev, V., Tsourouktsoglou, T.-D., Boeing, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.09.455510 · Cited by 5
Universal Digital High Resolution Melt for the detection of pulmonary mold infectionsPreprint
Goshia, T., Aralar, A., Wiederhold, N. P., Jenks, J. D., Mehta, S. R., Sinha, M., Karmakar, A., Sharma, A., Shrivastava, R., Sun, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.09.566457 · Cited by 3
“Invasive mold infections (IMI) cause millions of infections globally and account for an estimated 1.6 million deaths annually(Bongomin et al. 2017).”
BackgroundInfluentialExtracellular vesicles produced during fungal infection in humans are immunologically activePreprint
Rezende, C. P., dos Santos, P. W. D. S., Piraine, R. E. A., Silvestrini, V. C., Barbosa, J. C. J., Valera, F. C. P., Tamashiro, E., Gondim, G. G. P., Quintana, S. M., Calado, R. T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.20.585987 · Cited by 3
Jiang, J. B., Keniya, M. V., Puri, A., Zhan, X., Cheng, J., Wang, H., Lin, G., Lee, Y.-K., Jaber, N., Hassoun, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.596243 · Cited by 3
Pathogenicity is associated with population structure in a fungal pathogen of humansPreprint
Hatmaker, E. A., Barber, A. E., Drott, M. T., Sauters, T. J. C., Alastruey‐Izquierdo, A., Garcia‐Hermoso, D., Kurzai, O., & Rokas, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.05.602241 · Cited by 3
Wang, C.-Y., Wang, T.-J., Wu, Y.-C., & Hsu, C.-Y. (2024) · Acute and Critical Care · doi:10.4266/acc.2024.00843 · Cited by 2
“Among critically ill patients, invasive candidiasis is the most prevalent invasive fungal infection [3], with an estimated global incidence of around 700,000 cases annually [4].”
An Update on Fungal Orbital Infections
Chiou, C. A., & Yoon, M. K. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000407 · Cited by 3
Cantelli, B. A. M., Segura, G. G., Bitencourt, T. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050563 · Cited by 2
“Most dermatophytoses are superficial but may become deep infections when associated with a poor general health status of the patient [7].”
BackgroundSimilarity searching for anticandidal agents employing a repurposing approach
Rodríguez‐Villar, K., Cortés‐Benítez, F., Palacios‐Espinosa, J. F., & Pérez‐Villanueva, J. (2023) · Molecular Informatics · doi:10.1002/minf.202300206 · Cited by 2
Nanomedicines in the Treatment of Fungal Diseases
Ahsan, A., Aslam, Q.-U.-A., & Prestidge, C. A. (2023) · Learning materials in biosciences · doi:10.1007/978-981-99-7626-3_8 · Cited by 4
How can we optimize antifungal use and stewardship in the treatment of acute leukemia?
Taynton, T., Allsup, D. J., & Barlow, G. D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383401 · Cited by 2
“The overall global burden of fungal disease is substantial, with over a billion people infected with superficial dermatoses [7].”
Burden of Fungal Coinfections with HIV in Sub-Saharan Africa: Prevalence and Implications
Odoom, A., & Ofosu, W. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.115137 · Cited by 3
An Update on Human Fungal Diseases: A Holistic Overview
Singh, S., Vijayaraghavan, P., Devi, S., & Hameed, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_1 · Cited by 3
Insights into the origin, hybridisation and adaptation of Candida metapsilosis hybrid pathogens
del Olmo, V., Redondo-Río, Á., García, A. B., Limtong, S., Saus, E., & Gabaldón, T. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012864 · Cited by 2
“Yet, each year fungi kill over two million people [7] and cause a range of superficial or invasive infections affecting more than a billion people [8].”
Abubakar, H., Alam, O., Mukhtar, T., et al. (2024) · Journal of Biochemicals and Phytomedicine · doi:10.34172/jbp.2024.7 · Cited by 2
“…dimorphic fungi like Histoplasma capsulatum, and Mucormycetes continue to be the main fungal pathogens in charge of the majority of cases of serious fungal disease, despite the fact that the epidemiology of fungal diseases has significantly changed over the past few decades (Bongomin et al., 2017).”
InfluentialHoffman, J. J. S. L., Arunga, S., Matayan, E., et al. (2025) · Wellcome Open Research · doi:10.12688/wellcomeopenres.21390.1 · Cited by 2
“Accounting for 20–60% of diagnosed corneal infections in tropical regions, FK stands as a substantial subset of microbial keratitis (MK) 4 .”
Cracks in the Curriculum: The Hidden Deficiencies in Fungal Disease Coverage in Medical Books
ROST, I. H., da Rosa, M. M., BELARDINELLI, S. D. O., CASANI, E. H., Macelaro, G. P., GIORDANI, C. D. S., BORSA, E. P., FERREIRA, A. L. C. D. S., TAKEDA, L. N., & Pasqualotto, A. C. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf145 · Cited by 2
“Fungal infections are an increasing public health concern, causing > 3.8 million deaths annually [1, 2].”
InfluentialDermatological Fungal Neglected Tropical Diseases
Santos, D. W. D. C. L., de Azevedo, C. D. M. P. E. S., & Queiroz‐Telles, F. (2025) · Current Fungal Infection Reports · doi:10.1007/s12281-025-00501-2 · Cited by 2
Svenson, C. S., Bruhn, F. R. P., Becker, C. E. S., Jara, M. C., & Nascente, P. D. S. (2025) · Brazilian Journal of Biology · doi:10.1590/1519-6984.288825 · Cited by 2
Gallego‐Cartagena, E., Morgado‐Gamero, W., Moya, I. D., Díaz‐Uribe, C., Parody, A., Morillas, H., Bayona-Pacheco, B. L., Pellegrin, G., & Castañeda, D. M. A. (2025) · Environmental Microbiology Reports · doi:10.1111/1758-2229.70078 · Cited by 2
Emery, C. L., Dhiman, N., Chow, S.-K., Peterson, G., Granato, P. A., Bernier, B., & Farhang, J. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00362-25 · Cited by 4
“The annual global incidence of invasive candidiasis is 700,000 cases (3), with a fatality rate of approximately 40% (4).”
Novel infection by Mucor hiemalis kills Caenorhabditis hosts through intestinal perforation
Ni, J., Weigand, S., & Sowa, J. N. (2026) · Infection and Immunity · doi:10.1128/iai.00310-25 · Cited by 3
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.